Total Lymphoid Irradiation in Refractory Systemic Lupus Erythematosus

  1. ELDAD BEN-CHETRIT, M.D.;
  2. DAVID J. GROSS, M.D.;
  3. ABRAHAM BRAVERMAN, M.D.;
  4. ZEEV WESHLER, M.D.;
  5. ZVI FUKS, M.D.;
  6. SHIMON SLAVIN, M.D.; and
  7. MARCEL ELIAKIM, M.D.
  1. Jerusalem
    , Israel

    Abstract

    In two patients with systemic lupus erythematosus, conventional therapy was considered to have failed because of persistent disease activity and unacceptable side effects. Both were treated with total lymphoid irradiation without clinical benefit, despite adequate immunosuppression as documented by markedly reduced numbers of circulating T lymphocytes and T-lymphocytedependent proliferative responses in vitro. The first patient developed herpes zoster, gram-negative septicemia, neurologic symptoms, and deterioration of lupus nephritis. The second patient developed massive bronchopneumonia, necrotic cutaneous lesions, and progressive nephritis and died 2 weeks after completion of radiotherapy. These observations, although limited to two patients, indicate that total lymphoid irradiation in patients with severe systemic lupus erythematosus should be regarded as strictly experimental.

    Article and Author Information

    • ▸From the Departments of Medicine A, Oncology, and Bone Marrow Transplantation and Immunobiology Research, Hadassah University Hospital; Jerusalem, Israel.

    • ▸Requests for reprints should be addressed to Shimon Slavin, M.D.; Department of Bone Marrow Transplantation and Immunobiology Research, Hadassah University Hospital; IL-91120 Jerusalem, Israel.

    « Previous | Next Article »Table of Contents